ES2790875T3 - Compuesto antimicótico - Google Patents

Compuesto antimicótico Download PDF

Info

Publication number
ES2790875T3
ES2790875T3 ES15808770T ES15808770T ES2790875T3 ES 2790875 T3 ES2790875 T3 ES 2790875T3 ES 15808770 T ES15808770 T ES 15808770T ES 15808770 T ES15808770 T ES 15808770T ES 2790875 T3 ES2790875 T3 ES 2790875T3
Authority
ES
Spain
Prior art keywords
compound
salt
formula
revision
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15808770T
Other languages
English (en)
Spanish (es)
Inventor
Mihiro Sunose
Thomas Christopher Colley
Kazuhiro Ito
Garth Rapeport
Peter Strong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulmocide Ltd
Original Assignee
Pulmocide Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmocide Ltd filed Critical Pulmocide Ltd
Application granted granted Critical
Publication of ES2790875T3 publication Critical patent/ES2790875T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F1/00Details not covered by groups G06F3/00 - G06F13/00 and G06F21/00
    • G06F1/26Power supply means, e.g. regulation thereof
    • G06F1/32Means for saving power
    • G06F1/3203Power management, i.e. event-based initiation of a power-saving mode
    • G06F1/3234Power saving characterised by the action undertaken
    • G06F1/325Power saving in peripheral device
    • G06F1/3268Power saving in hard disk drive
    • GPHYSICS
    • G11INFORMATION STORAGE
    • G11CSTATIC STORES
    • G11C11/00Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor
    • G11C11/21Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements
    • G11C11/34Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices
    • G11C11/40Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices using transistors
    • G11C11/401Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices using transistors forming cells needing refreshing or charge regeneration, i.e. dynamic cells
    • G11C11/4063Auxiliary circuits, e.g. for addressing, decoding, driving, writing, sensing or timing
    • G11C11/407Auxiliary circuits, e.g. for addressing, decoding, driving, writing, sensing or timing for memory cells of the field-effect type
    • G11C11/4074Power supply or voltage generation circuits, e.g. bias voltage generators, substrate voltage generators, back-up power, power control circuits

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES15808770T 2014-12-05 2015-12-04 Compuesto antimicótico Active ES2790875T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14196662 2014-12-05
PCT/GB2015/053731 WO2016087878A1 (en) 2014-12-05 2015-12-04 Antimycotic compound

Publications (1)

Publication Number Publication Date
ES2790875T3 true ES2790875T3 (es) 2020-10-29

Family

ID=52006914

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15808770T Active ES2790875T3 (es) 2014-12-05 2015-12-04 Compuesto antimicótico
ES15817507T Active ES2786374T3 (es) 2014-12-05 2015-12-04 Compuesto antimicótico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15817507T Active ES2786374T3 (es) 2014-12-05 2015-12-04 Compuesto antimicótico

Country Status (18)

Country Link
US (12) US10106531B2 (enExample)
EP (2) EP3227277B1 (enExample)
JP (2) JP6666345B2 (enExample)
KR (1) KR102579848B1 (enExample)
CN (2) CN107001343B (enExample)
AU (1) AU2015356795B2 (enExample)
BR (1) BR112017008481B1 (enExample)
CA (1) CA2963625C (enExample)
DK (2) DK3227277T3 (enExample)
EA (1) EA033736B1 (enExample)
ES (2) ES2790875T3 (enExample)
HU (2) HUE048905T2 (enExample)
IL (1) IL251631B (enExample)
MX (1) MX370412B (enExample)
PL (1) PL3227277T3 (enExample)
PT (1) PT3227277T (enExample)
SG (1) SG11201702835RA (enExample)
WO (2) WO2016087880A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE048905T2 (hu) 2014-12-05 2020-08-28 Pulmocide Ltd Antimikotikus vegyület
JP6694886B2 (ja) 2014-12-18 2020-05-20 プルモシデ リミテド 4,5−ジヒドロ−6H−チエノ[3,2−d]ベンゾアゼピン誘導体及び呼吸器合胞体ウイルス(RSV)感染を治療するためのその使用
JP6811727B2 (ja) 2015-05-21 2021-01-20 プルモシデ リミテド 抗真菌性の4−(4−(4−(((3r,5r)−5−((1h−1,2,4−トリアゾール−1−イル)メチル)−5−(2,4−ジフルオロフェニル)テトラヒドロフラン−3−イル)メトキシ)−3−メチルフェニル)ピペラジン−1−イル)−n−(2−ヒドロキシシクロヘキシル)ベンズアミド、又はその医薬として許容し得る塩
WO2017093491A1 (en) * 2015-12-04 2017-06-08 Pulmocide Limited Antimycotic triazole compound
WO2018096405A1 (en) * 2016-11-28 2018-05-31 Cellix Bio Private Limited Compositions and methods for the treatment of oral infectious diseases
WO2018115319A2 (en) 2016-12-23 2018-06-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases
GB201917867D0 (en) * 2019-12-06 2020-01-22 Pulmocide Ltd Polymorphs
EP3858357A1 (en) * 2020-01-28 2021-08-04 Diaccurate Use of azole compounds to stimulate the immune system and as inhibitors for s-pla2gib
RU2770598C1 (ru) * 2021-06-29 2022-04-18 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) ПРИМЕНЕНИЕ ПРОТИВОГРИБКОВОГО СРЕДСТВА НА ОСНОВЕ 2-((4-R1-5-R2-3-(ЭТОКСИКАРБОНИЛ)ТИОФЕН-2-ИЛ)АМИНО)-4-ОКСО-4-R3-БУТ-2-ЕНОВЫХ КИСЛОТ ПО ОТНОШЕНИЮ К Candida aldicans
WO2025114603A1 (en) 2023-11-30 2025-06-05 Basilea Pharmaceutica International Ag, Allschwil Pharmaceutical combinations for use in the treatment of fungal infections

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5533466A (en) * 1978-07-14 1980-03-08 Janssen Pharmaceutica Nv Novel azole derivatives and their manufacture
CH655103A5 (de) * 1983-03-11 1986-03-27 Sandoz Ag Azolderivate, verfahren zu ihrer herstellung und ihre verwendung.
CA1292472C (en) 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
DE3609598A1 (de) * 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
JPH0717634B2 (ja) 1987-11-20 1995-03-01 シェリング・コーポレーション トリ‐およびテトラ‐置換‐オキセタンおよびテトラヒドロフランおよびその中間体
US5039678A (en) 1989-03-23 1991-08-13 Wake Forest University Method of increasing cranial vessel proliferation by administering nimodipine
US5039676A (en) 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US5403937A (en) * 1993-04-30 1995-04-04 Schering Corporation Process for preparing intermediates for the synthesis of antifungal agents
US5714490A (en) 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
AU681753B2 (en) 1993-12-21 1997-09-04 Merck Sharp & Dohme Corp. Tetrahydrofuran antifungals
US5486625A (en) 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
IL118464A (en) 1995-06-02 2000-08-13 Schering Corp (2R-cis)-4-¬4-¬4-¬4¬¬-5-(2',4 dihalophenyl)-tetrahydro-5-(1-H-1,2,4,triazol-1-yl-methyl)furan-3-yl(methoxy¾phenyl¾-1-piperazinyl¬phenyl2,4,dihydro2¬(5)-1-ethyl-2-(5)hydroxy propyl¾-3H-1,2,4-triazol-3-one and pharmaceutical compositions comprising them
EP0957101A1 (en) 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
EP2090165A3 (en) 2001-04-03 2012-03-28 Schering Corporation Antifungal composition with enhanced bioavailability
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
ES2649995T3 (es) * 2011-07-18 2018-01-16 Merck Patent Gmbh Benzamidas
WO2013036866A1 (en) 2011-09-07 2013-03-14 The Johns Hopkins University Itraconazole analogs and use thereof
HUE048905T2 (hu) 2014-12-05 2020-08-28 Pulmocide Ltd Antimikotikus vegyület
GB201917867D0 (en) 2019-12-06 2020-01-22 Pulmocide Ltd Polymorphs

Also Published As

Publication number Publication date
WO2016087878A1 (en) 2016-06-09
JP6669751B2 (ja) 2020-03-18
US11008307B2 (en) 2021-05-18
US20190023697A1 (en) 2019-01-24
US20200239453A1 (en) 2020-07-30
DK3227277T3 (da) 2020-04-27
US10487073B2 (en) 2019-11-26
US11661415B2 (en) 2023-05-30
US20200002320A1 (en) 2020-01-02
BR112017008481B1 (pt) 2022-09-06
US20170320858A1 (en) 2017-11-09
US20200399253A1 (en) 2020-12-24
IL251631A0 (en) 2017-06-29
CN112375073A (zh) 2021-02-19
CN107001343B (zh) 2020-12-11
MX370412B (es) 2019-12-11
US10800762B2 (en) 2020-10-13
IL251631B (en) 2020-05-31
US10106531B2 (en) 2018-10-23
SG11201702835RA (en) 2017-05-30
US12269814B2 (en) 2025-04-08
CN107001343A (zh) 2017-08-01
MX2017007188A (es) 2017-08-28
US20170037035A1 (en) 2017-02-09
CA2963625C (en) 2023-08-22
JP6666345B2 (ja) 2020-03-13
HUE048905T2 (hu) 2020-08-28
US20210048874A1 (en) 2021-02-18
US10662179B2 (en) 2020-05-26
JP2017536385A (ja) 2017-12-07
US20230295133A1 (en) 2023-09-21
BR112017008481A2 (pt) 2018-01-09
EP3227278A1 (en) 2017-10-11
HK1244795A1 (en) 2018-08-17
EP3227278B1 (en) 2020-02-05
WO2016087880A1 (en) 2016-06-09
AU2015356795B2 (en) 2020-01-16
CA2963625A1 (en) 2016-06-09
PT3227277T (pt) 2020-04-14
PL3227277T3 (pl) 2020-08-10
EA201791174A1 (ru) 2017-10-31
US10093659B2 (en) 2018-10-09
US20200031809A1 (en) 2020-01-30
EA033736B1 (ru) 2019-11-20
EP3227277A1 (en) 2017-10-11
CN112375073B (zh) 2024-04-16
JP2017536382A (ja) 2017-12-07
DK3227278T3 (da) 2020-04-27
HUE048685T2 (hu) 2020-07-28
US20190023696A1 (en) 2019-01-24
NZ730861A (en) 2021-04-30
KR102579848B1 (ko) 2023-09-18
US10344022B2 (en) 2019-07-09
US20190276441A1 (en) 2019-09-12
AU2015356795A1 (en) 2017-04-27
US10450304B2 (en) 2019-10-22
ES2786374T3 (es) 2020-10-09
KR20170088850A (ko) 2017-08-02
US10858345B2 (en) 2020-12-08
US20210238169A1 (en) 2021-08-05
EP3227277B1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
ES2790875T3 (es) Compuesto antimicótico
US20190202813A1 (en) Process for preparing 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluoro-phenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-N-((1S,2S)-2-hydroxycyclohexyl)benzamide or a pharmaceutically acceptable salt thereof
NZ730861B2 (en) Antimycotic compound
HK1244795B (en) Antimycotic compound
BR112017020807B1 (pt) Composto 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-triazol-1-il)metil)-5-(2,4- difluorofenil)tetra-hidrofuran-3-il)metóxi)-3-metilfenil)piperazin-1-il)-n-(2- hidroxiciclo-hexil) benzamida antifúngica, seu processo de preparação, e composição farmacêutica
HK1252779B (en) Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1-yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof